Indo Us Biotech cash flow

Latest FY26
Cash from operations
−₹16.1cr−₹1.4 cr in FY25
Capital spending
₹2.4crNo figure a year before
Free cash flow
−₹18.5cr−₹1.4 cr in FY25
Cash from financing
₹24.4cr−₹1.5 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
Adjustments to reconcile profit — non-cash items
—−0.91.1
—0.00.0
—2.20.0
—0.00.0
—0.00.0
Changes in working capital
—−29.3−19.0
—−0.93.6
—0.00.4
—0.00.0
—−0.7−3.2
—0.00.5
—−0.50.4
—0.10.0
—0.30.0
Cash from operating activities
5.013.916.5
—−29.6−16.2
—−15.60.4
—0.00.1
—0.01.5
—0.40.4
—−16.1−1.4
Cash from investing activities
—−2.40.0
—0.00.9
—0.00.0
—0.90.0
—−0.00.1
—3.3−0.8
Cash from financing activities
—−2.00.5
—−24.20.0
—−2.21.5
—0.00.5
—24.4−1.5
—11.6−3.7
—0.20.0
—11.9−3.7
Reference items
8.717.018.9
9.0%15.4%18.2%
−18.5−18.5−1.4
—1.5—
−₹9.22−₹9.22−₹0.71
—−1.23×−0.09×
—0.40.4
—2.21.5
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

INDOUS₹78.36

Indo Us Biotech Limited

· FMCG & Retail
₹ CrorePeersKOHINOORNATHBIOGENAGRITECHSARVESHWARSUKHJITSREGAALBSHSLGULPOLYMcap ₹157 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation1.1-0.9—
+ Impairment Loss / (Reversal)0.00.0—
+ Finance Costs0.02.2—
+ Interest Income0.00.0—
+ Share-based Payments0.00.0—
Changes in Working Capital
+ Inventories-19.0-29.3—
+ Trade Receivables — Current3.6-0.9—
+ Other Current Assets0.40.0—
+ Other Non-current Assets0.00.0—
+ Trade Payables — Current-3.2-0.7—
+ Other Financial Liabilities — Current0.50.0—
+ Other Current Liabilities0.4-0.5—
+ Provisions — Current0.00.1—
+ Provisions — Non-current0.00.3—
Cash from Operating Activities
Profit Before Tax (per I/S)16.513.95.0
+ Total Adjustments (incl. Working Capital)-16.2-29.6—
Cash from Operations (pre-tax)0.4-15.6—
+ Interest Received — Operating0.10.0—
+ Interest Paid — Operating1.50.0—
+ Income Taxes Paid0.40.4—
Cash from Operating Activities-1.4-16.1—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)0.0-2.4—
+ Acq of Investment Property0.90.0—
+ Disp of Investment Property0.00.0—
+ Receipts on Futures / Forwards / Options / Swaps0.00.9—
+ Interest Received — Investing0.1-0.0—
Cash from Investing Activities-0.83.3—
Cash from Financing Activities
+ Proceeds from Borrowings0.5-2.0—
+ Repayment of Borrowings0.0-24.2—
+ Interest Paid1.5-2.2—
+ Dividends Paid0.50.0—
Cash from Financing Activities-1.524.4—
Net Changes in Cash (pre-FX)-3.711.6—
+ Effect of FX Rate Changes on Cash0.00.2—
Net Changes in Cash-3.711.9—
Reference Items
EBITDA18.917.08.7
EBITDA Margin %18.2315.409.02
Free Cash Flow (CFO − Capex)-1.4-18.5-18.5
Free Cash Flow to Equity—1.5—
Free Cash Flow per Basic Share-0.71-9.22-9.22
Cash Flow to Net Income-0.09-1.23—
Cash Paid for Taxes0.40.4—
Cash Paid for Interest1.52.2—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.